Kuehn Law is investigating Corcept Therapeutics for allegedly failing to disclose FDA concerns about the clinical development of relacorilant, a drug candidate for Cushing's syndrome. The company reportedly promoted expected FDA approval but did not reveal that the FDA had expressed doubts about the drug's effectiveness and that its approval faced significant risks. This lawsuit could impact shareholders who bought Corcept stock before October 31, 2024, as they may have grounds to claim breach of fiduciary duty by company officers and directors. Shareholders are encouraged to contact Kuehn Law to explore their legal options.
Fortuna Mining Corp. held its 2026 annual general meeting with 66.81% shareholder turnout. All business matters were approved, including the appointment of auditors, election of all nominated directors, and approval of the company's Share Unit Plan. ...
The QAIAx AI City Hall Project has launched the world's first federally registered clinical trial involving AI-governed smart microcities. These dome-enclosed communities integrate humanoid robots and quantum AI to manage public administration and pr...
SCOR announced that an arbitration tribunal confirmed the validity of reinsurance treaties made with Covéa in June 2021, involving the transfer of 30% of SCOR's Life & Health portfolio. The tribunal ruled in favor of Covéa, awarding $488.3 million in...
SCOR announced that an arbitration tribunal upheld the validity of retrocession treaties made with Covéa in June 2021, involving the transfer of 30% of SCOR's Life & Health portfolio in Ireland. The tribunal awarded Covéa compensation of USD 488.3 mi...
Lifestyle expert Marisa Brahney highlights simple and fun ways to celebrate America's 250th birthday this summer, including enjoying Northwest-grown sweet cherries, affordable travel with Travelodge by Wyndham near national parks, and supporting Amer...
